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Key Points
• VWF variants
c.2365A.G and
c.2385T.C in-
dependently influence
VWF biosynthesis and
clearance, increasing
VWF plasma levels.
•Commonly inherited
VWF variants can di-
rectly influence the
protein and may con-
tribute to hemostatic
and thrombotic disease
risk/severity.
Plasma levels of von Willebrand factor (VWF) vary considerably in the general population
and this variation has been linked to several genetic and environmental factors. Genetic
factors include 2 common single nucleotide variants (SNVs) located in VWF, rs1063856
(c.2365A.G) and rs1063857 (c.2385T.C), although to date the mechanistic basis for their
association with VWF level is unknown. Using genotypic/phenotypic information from a
European healthy control population, in vitro analyses of recombinant VWF expressing
both SNVs, and in vivo murine models, this study determined the precise nature of their
associationwith VWF level and investigated themechanism(s) involved. Possession of either
SNV corresponded with a signiﬁcant increase in plasma VWF in healthy controls (P, .0001).
In vitro expression conﬁrmed this observation and highlighted an independent effect for
each SNV (P , .0001 and P , .01, respectively), despite close proximity and strong linkage
disequilibrium between them both. The inﬂuence of c.2365A.G on VWF levels was also
conﬁrmed in vivo. This increase in VWF protein corresponded to an increase in VWF
messenger RNA (mRNA) resulting, in part, from prolonged mRNA half-life. In addition,
coinheritance of both SNVs was associated with a lower VWF propeptide-to-VWF antigen
ratio in healthy controls (P , .05) and a longer VWF half-life in VWF knockout mice
(P , .0001). Both SNVs therefore directly increase VWF plasma levels through a combined
inﬂuence on VWF biosynthesis and clearance, and may have an impact on disease
phenotype in both hemostatic and thrombotic disorders.
Introduction
von Willebrand factor (VWF) is an important plasma glycoprotein that performs 2 major hemostatic
functions. It recruits platelets to sites of vascular injury and carries coagulation factor VIII (FVIII),
protecting FVIII from degradation while conveying it to sites of vascular injury.1 There is considerable
natural variation in VWF plasma levels; between 50% and 200% of average normal levels are seen in
95% of the general population.2
In humans, there is strong evidence of a genetic influence on VWF levels. In pedigree analyses, the
attributable genetic influence is ;30%,3 whereas twin studies have shown that it is ;70%.4 It is well
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known that the ABO blood group locus accounts for;30% of this
heritable influence on VWF levels,5,6 but recent association
studies have also highlighted the influence of genetic variation at
the VWF locus. The Cohorts for Heart and Aging Research in
Genome Epidemiology study indicated that the common VWF
single nucleotide variant (SNV) rs1063857 was significantly
associated with interindividual variation in plasma VWF levels
(P 5 1.7 3 10232).7 Furthermore, a study of African Americans
identified several VWF SNV influencing levels of the protein
including the frequently inherited rs1063856, found to result in a
significant increase in VWF levels (1.05 3 1029).8 Other studies
have reported similar observations for rs1063856,9-11 rs1063857,12-15
or both.16
rs1063856 (c.2365A.G; p.T789A) and rs1063857 (c.2385T.C;
p.Y7955) are reported to be in strong linkage disequilibrium (LD;
r2 5 0.980-1.000)17 and have a minor allele frequency of ;33%
(ranging from 9% in east Asian populations to 64% in African
populations).17,18 They are located in VWF exon 18, which encodes
part of the D9D3 assembly, functionally important for binding of
VWF to FVIII (VWF:FVIIIB). Notably, both rs10638567,8 and
rs106385719 have also been found to have a significant influence
on FVIII procoagulant activity (FVIII:C). However, despite their
significant association with VWF and FVIII levels, no studies have
investigated the mechanistic basis for this influence. The aim of this
study was therefore to investigate the mechanism(s) by which these
SNVs are able to influence VWF and FVIII levels using a combined
in vitro and in vivo approach.
Methods
Study population and genotypic/phenotypic analysis
European (predominantly white) healthy control individuals (n 5
1166; Table 1) were recruited as part of the Molecular and Clinical
Markers for the Management and Diagnosis of Type 1 von
Willebrand Disease (MCMDM-1VWD) study. Available phenotypic
data for VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:
RCo), collagen binding (VWF:CB), propeptide (VWFpp), FVIII:C,
and VWF:FVIIIB were measured as previously described.20-24
Genotypic analysis of SNV c.2365A.G and c.2385T.C was
performed using the MassARRAY matrix-assisted laser desorption
ionization–time of flight system (Sequenom Inc, San Diego, CA)
as described.25 Experiments involving healthy control individuals
were performed with the approval of the Sheffield Research Ethics
Committee. In accordance with the Declaration of Helsinki,
informed consent was obtained from all individuals at recruitment by
signing a consent form in the individual’s own language.
Generation of human and murine VWF
expression plasmids
A pcDNA3.1/Hygro(2) mammalian expression plasmid (Thermo
Fisher Scientific, Paisley, United Kingdom) containing full-length
human VWF complementary DNA (cDNA; vWF-pcDNA3.1)
was generated as previously described.26 Plasmids expressing
c.2365A.G (p.T789A), c.2385T.C (p.Y7955) or both SNVs
in cis (c.[2365A.G;2385T.C]; p.[T789A;Y7955]) were gener-
ated using a QuikChange Lightning site-directed mutagenesis
kit (Agilent Technologies LDA UK Ltd, Stockport, United Kingdom).
Successful mutagenesis was confirmed via Sanger sequence
analysis.
Murine Vwf (mVWF) cDNA was cloned into pSC11 under the
transthyretin promoter as previously described.27 Amino acid
alignment demonstrated that the human VWF (hVWF) variants
were poorly conserved across species (see Figure 6A), with
nucleotide alignment between mVWF and hVWF indicating that
mVWF encodes the nonreference (NR) hVWF allele for each
corresponding SNV (see Figure 6B). mVWF was “humanized” by
site-directed mutagenesis using a QuikChange II XL kit (Stratagene,
La Jolla, CA) to alter the sequence to c.[2365G.A;2367T.C]
(p.A789T), c.2385C.T (p.Y7955) or c.[2365G.A;2367T.C;
2385C.T] (p.[A789T;Y7955]).
In vitro measurement of VWF:Ag
HEK293T cells were maintained in Dulbecco modified Eagle
medium containing GlutaMAX supplemented with 10% vol/vol fetal
bovine serum (Thermo Fisher Scientific). Cell transfections were
conducted in 9.6 cm2 wells using Xfect (Takara Bio Europe S.A.S.,
Saint-Germain-en-Laye, France). To summarize, 2.5 mg of wild-type
(WT) or variant VWF expression plasmid (or 1.25 mg of WT and
variant VWF for 50:50 cotransfections) was transfected and left to
incubate at 37°C/5% CO2 for 24 hours before replacement of the
culture media. Following a further 48-hour incubation, culture media
was collected and the cells lysed in 300 mL of 13 passive lysis
buffer (Promega UK Ltd, Southampton, United Kingdom). Mea-
surement of VWF:Ag in collected media and lysates was performed
using a matched-pair antibody human VWF enzyme-linked immu-
nosorbent assay (ELISA; Enzyme Research Laboratories Ltd,
Swansea, United Kingdom) according to the manufacturer’s
specifications.
mRNA analysis
HEK293T cells were cultured and transfected as stated and
harvested cells were centrifuged at 4000g for 5 minutes.
Messenger RNA (mRNA) was extracted from pelleted cells using
an EZ-RNA total RNA isolation kit (Geneflow Ltd, Lichfield, United
Kingdom) and reverse transcribed using a QuantiTect reverse
transcription kit (Qiagen Ltd, Manchester, United Kingdom)
following manufacturer guidelines. Quantitative reverse transcrip-
tion polymerase chain reaction (qRT-PCR) assays measuring both
the target (VWF; Hs01109446_m1) and an endogenous control
(b2 microglobulin [B2M]; Hs00984230_m1) in tandem were
performed on a 7900HT real-time PCR system using TaqMan
gene expression master mix (Thermo Fisher Scientific) according to
manufacturer guidelines. Following assay completion, calculation
of DD cycle threshold28 was used to indicate relative VWF RNA
quantity.
mRNA half-life was measured using the same qRT-PCR protocol,
but at 24 hours posttransfection, cells were treated with 5 mg/mL
actinomycin D (Thermo Fisher Scientific). Cells were harvested at
0, 2, 3, and 4 hours posttreatment and half-life calculated as the
time at which mRNA level was 50% of the level detected at 0 hours
posttreatment.29
Hydrodynamic injection
Expression of mVWF cDNA in vivo was induced by hydrodynamic
tail vein injection in VWF/FVIII double-knockout (DKO) C57Bl/6
mice.30 Plasma was collected via cardiac puncture 3 days
postinjection. VWF:Ag was measured by ELISA using Dako
(Glostrup, Denmark) anti-VWF antibodies for capture and detection
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(A0082 and P0226). All animal experiments were performed with
the approval of the Queen’s University Animal Care Committee.
VWF half-life evaluation and FVIII stabilization
VWF knockout (KO) mice received 200 U/kg WT or p.[A789T;
Y7955] plasma-derived mVWF (FVIII-free; produced in VWF/FVIII
DKO mice) by tail-vein injections. VWF:Ag was quantified prior to
plasma pooling, and reconstituted for both WT and p.[A789T;
Y7955] to equimolar concentrations (20 U/mL) using VWF/FVIII
DKO mouse pooled plasma as required as previously
described.31,32 VWF:Ag levels were measured by Dako ELISA
and endogenous murine FVIII:C was measured by chromogenic
assay (Chromogenix Coatest SP Factor VIII; Diapharma Group Inc,
West Chester, OH). VWF:Ag was measured relative to a 5-minute
recovery (set to 100%) and half-life evaluated using a 1-phase
exponential decay model in GraphPad Prism version 7.03
(GraphPad Software Inc, La Jolla, CA).
Statistical and in silico analysis
Statistical analyses were performed using GraphPad. Comparisons
of $3 groups were performed using either a 1-way/2-way analysis
of variance (ANOVA; to compare mean values) or a Kruskal-Wallis
test (to compare median values).33 Multivariable linear regression
analysis to test associations between variables was performed as
previously described.34 All models were adjusted for age and ABO
blood group (and either SNV c.2365A.G or c.2385T.C; 14
models in total) using IBM SPSS v24.0 for Windows 2016
(Armonk, New York, NY).
In silico protein, RNA, and splicing predictions were performed
using several online tools as specified in supplemental Table 1. In
silico analysis to determine LD was performed using Haploview
v4.2.35
Results
Association of c.2365A>G and c.2385T>C with
VWF levels
To confirm previous observations, that is, that c.2365A.G and
c.2385T.C act as frequent small-scale genetic modifiers, the
association between VWF SNV genotype and VWF levels was
investigated in 1166 healthy control individuals (HCs). Analysis
confirmed that the NR allele for each SNV was associated with
significantly higher VWF:Ag levels (P , .0001; reference [R]/R, 93
and 93 IU/dL; R/NR, 98 and 98 IU/dL; NR/NR, 114 and 110 IU/dL
c.2365A.G and c.2385T.C, respectively; Figure 1A-B) and when
both SNVwere combined (P, .0001; R/R, 93 IU/dL; R/NR, 98 IU/dL;
NR/NR, 114 IU/dL; Figure 1C). This association was also observed
when accounting for ABO blood group (O, P 5 .0005; non-O,
P5 .0009; supplemental Figure 1A-B), which was confirmed by linear
regression analysis (Table 1). However, analysis of FVIII:C levels
showed no association with genotype (Figure 1D-F; Table 1), although,
there was a trend toward increased FVIII:C levels associated with the
SNV NR allele in the HCs with O blood group, but not in those with
non-O blood group (supplemental Figure 1C-D). Likewise, SNV
genotype was not associated with VWF:RCo or VWF:CB levels
(Table 1; supplemental Figure 2A-B).
In vitro expression of recombinant VWF protein
and mRNA
In silico analysis of the HC genotype data confirmed that the SNV
were in strong LD (r2 5 0.991) suggesting that the observed
association with VWF:Ag levels could be attributable to only 1 of
the 2 SNVs or to both. To investigate this possibility and to verify the
observed association in HCs, VWF-expressing plasmids encoding
each SNV independently or together in cis were generated and
VWF expression compared against a WT plasmid. Expression of
both SNVs independently and together in cis resulted in an increase
in both retained and secreted VWF expression (P, .0001, P, .01,
and P , .0001, respectively; Figure 2). Despite the increased
expression, no significant differences were observed in intracellular
localization or pseudo–Weibel-Palade body formation betweenWT
and variant VWF (supplemental Methods; supplemental Figure 3).
Given that both SNVs appeared to have an independent effect on
VWF:Ag level, in silico and/or in vitro tools were used to predict
whether nonsynonymous SNV c.2365A.G would have an impact
on the VWF protein and also to predict whether either SNV would
have an influence on mRNA processing or stability. c.2365A.G
was not predicted to affect the protein structure/function and
neither SNV was predicted to affect microRNA-binding sites nor
influence splicing (supplemental Methods; supplemental Table 1;
supplemental Figure 4). However, both were predicted to affect
mRNA secondary structure (supplemental Table 1; supplemental
Table 1. Population characteristics and regression analysis of VWF levels in the healthy control cohort
Variable Median (IQR)
c.2365A>G c.2385T>C
Coefficient b (95% CI) P Coefficient b (95% CI) P
VWF:Ag, n 5 1156 97 IU/dL (75, 121) 7.184 (4.380 to 9.988) ,.001 6.986 (4.173 to 9.799) ,.001
VWF:RCo, n 5 1155 87 IU/dL (65, 113) 2.215 (21.721 to 6.151) .270 1.744 (22.173 to 5.661) .382
FVIII:C, n 5 1161 101 IU/dL (77, 127) 1.112 (22.477 to 4.701) .543 0.719 (22.846 to 4.284) .692
VWF:CB, n 5 239 80 IU/dL (46, 119) 0.748 (210.754 to 12.250) .898 0.178 (211.097 to 11.454) .975
VWFpp, n 5 389 118 IU/dL (104, 135) 1.172 (22.674 to 5.018) .549 0.897 (22.922 to 4.716) .644
VWFpp/VWF:Ag, n 5 387* 1.24 (1.05, 1.48) 20.060 (20.114 to 20.006) .030 20.056 (20.111 to 20.002) .043
VWF:FVIIIB, n 5 181† 1.09 (0.98, 1.20) 0.011 (20.027 to 0.050) .563 0.013 (20.026 to 0.051) .520
ABO blood group data were available for n 5 1124 (n 5 481 [42.8%] blood group O).
CI, confidence interval; IQR, interquartile range.
*n 5 387 (1 individual was excluded from analyses because he or she was classified as an outlier [mean 1 3 standard deviations]).
†n 5 181 of 1166 healthy control individuals (median age, 39 years [range, 4-100]; n 5 497 [42.6%] male).
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Figure 5), which is known to influence mRNA stability and
translation efficiency.36 Analysis of cDNA isolated from cells
expressing each SNV independently showed an increase in VWF
mRNA expression (P, .01 and P, .05, respectively; Figure 3A-B),
with an additive increase observed when both SNV were expressed
in cis (P , .0001; Figure 3C).
Determination of mRNA half-life
Based on the observation that both SNVs result in increased mRNA
expression and a predicted effect on mRNA secondary structure,
the decision was taken to compare the half-life of the mRNA
generated by the WT expression plasmid against the half-life of
mRNAs generated by variant expression plasmids. The data
indicated that compared with the WT, both SNVs independently
prolong the half-life of the expressed VWF mRNA (Figure 4A-B).
In addition, the presence of both SNV in cis demonstrated a
cumulative increase in mRNA half-life (Figure 4C-D), highlighting a
direct correlation between prolonged mRNA half-life and the
observed increase in VWF mRNA and protein expression.
Association of c.2365A>G and c.2385T>C with
VWF activity
There was no observed difference in the multimer profiles of the
expressed recombinant VWF (supplemental Figure 6). In addition,
and in contrast to the previously reported type 2N mutation
c.2365A.C (p.T789P),37 neither SNV had a significant effect on
VWF:FVIIIB when investigated in HCs (Table 1; supplemental
Figure 2C) or when investigated in vitro (supplemental Methods;
supplemental Table 2). However, analysis did highlight that the
combined variant haplotype, p.[T789A;Y7955] VWF, had a slightly
decreased binding affinity to FVIII compared with WT VWF which
was likely due to a faster dissociation rate in spite of a similar
association rate (supplemental Methods; supplemental Table 2).
Association of c.2365A>G and c.2385T>C with VWFpp
and VWFpp/VWF:Ag ratio
Similar to the observed association between SNV genotype and
VWF:Ag levels, the NR allele was also linked to higher VWFpp
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Figure 1. Association between SNV genotype and median
VWF:Ag and FVIII:C levels in HCs. (A) SNV c.2365A.G and
VWF:Ag levels. (B) SNV c.2385T.C and VWF:Ag levels. (C)
Both SNVs in cis and VWF:Ag levels. (D) SNV c.2365A.G and
FVIII:C levels. (E) SNV c.2385T.C and FVIII:C levels. (F) Both
SNVs in cis and FVIII:C levels. Genotypes compared using a
Mann-Whitney U test (*P , .05; ****P , .0001). Bars indicate
95% CI. NR, nonreference allele; ns, not significant; R, reference
allele.
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levels in HCs (R/R, 117 IU/dL; R/NR, 119 IU/dL; NR/NR, 122
IU/dL), although this increase was not significant (Table 1;
supplemental Figure 2D). However, analysis did highlight a signif-
icant association between the NR allele and reduced VWFpp/VWF:
Ag ratio (P , .05; Figure 5), which was confirmed independently
for both c.2365A.G (P 5 .03) and c.2385T.C (P 5 .043) using
regression analysis (Table 1).
Characterization of VWF expression and half-life
in vivo
The influence of the c.[2365A.G;2385T.C] genotype on VWF
was also investigated using an in vivo mVWF model to complement
the in vitro findings. Expression of the single “humanized” mVWF
variants (c.[2365G.A;2367T.C]; p.A789T and c.2385C.T;
p.Y7955) or the combined in cis variant haplotype (c.[2365G.A;
2367T.C;2385C.T]; p.[A789T;Y7955]) was assessed 3 days
posthydrodynamic tail-vein injection of mVWF cDNA into VWF/FVIII
DKO mice. c.[2365G.A;2367T.C] (P , .0001) and both mVWF
variants in cis (P , .0001) had decreased expression compared
with WT, whereas c.2385C.T expression alone did not (P 5 .773)
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Figure 2. In vitro expression of recombinant VWF protein. (A) SNV
c.2365A.G. (B) SNV c.2385T.C. (C) Both SNVs in cis. Genotypes compared
using a 2-way ANOVA with the Tukey multiple comparisons test (*P , .05;
**P , .01; ***P , .001; ****P , .0001). Mean values for n 5 3 triplicate
measurements are shown (bars indicate standard error of the mean).
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Figure 3. In vitro expression of recombinant VWF mRNA. (A) SNV
c.2365A.G. (B) SNV c.2385T.C. (C) Both SNVs in cis. Genotypes compared
using an unpaired Student t test (*P , .05; **P , .01; ****P , .0001). Mean values for
n 5 3 triplicate measurements are shown (bars indicate standard error of the mean).
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(Figure 6C). The influence of the combined in cis variant haplotype
on plasma VWF:Ag levels was compared with WT over a 4-week
period. For all time points, the humanized mVWF demonstrated lower
plasma expression when compared with WT mVWF (Figure 6D).
Plasma-derived mVWF that was FVIII-free was generated by
hydrodynamic injection of the mVWF cDNA into VWF/FVIII DKO
mice. Pooled plasma was then infused by tail vein injection into
VWF KO mice and VWF half-life and endogenous FVIII:C
stabilization were measured. Both SNV in cis had a shorter
half-life than WT (2.53 vs 5.98 hours; P , .0001) (Figure 6E)
and impaired stabilization of endogenous FVIII:C (area under the
curve . 80% decrease; P , .001) (Figure 6F).
Discussion
This study used both in vitro and in vivo analyses with the aim of
determining how VWF SNV c.2365A.G and c.2385T.C influence
VWF and FVIII levels. Previous studies had linked both SNV to
variation in both VWF plasma and FVIII activity levels. Analysis in a
European HC population has confirmed that both act as frequent
small-scale genetic modifiers of VWF, showing that inheritance of the
NR allele of each SNV is linked to a significant increase in VWF:Ag.
However, analysis in this HC population notably did not show any
significant correlation with FVIII:C. Plasma VWF is known to
circulate in excess to plasma FVIII under normal conditions.38
Consequently, increases in VWF levels will have a limited impact on
FVIII levels, which is confirmed by recent data highlighting that for
every 1% change in VWF:Ag there is only a corresponding 0.54%
change in FVIII:C levels.39 This may suggest that a larger sample
cohort than the HC population used in this study would be required
to observe an impact of these SNV on FVIII. The fact that previous
studies investigating these SNV consistently reported lower levels
of significance for FVIII:C associations (P 5 3.6 3 1029, P 5 1.24
3 1026 and P 5 .02, respectively)7,8,10 compared with VWF:Ag
(P5 1.73 10232,P5 1.053 1029 and P5 .006, respectively)7,8,10
supports this hypothesis.
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In vitro expression of recombinant VWF not only verified that the NR
alleles resulted in higher VWF:Ag levels, but also highlighted that
both SNV independently increased VWF levels. Despite an overall
increase in total VWF expression, under all expressed conditions
the NR allele corresponded to a greater increase in retained VWF.
In vivo, VWF undergoes extensive posttranslational modification
and complex storage/secretion processes,40 but this regulated
secretory pathway is not present in HEK293T cells.41 Given that the
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mean levels of VWF secreted remained similar regardless of
whether c.2365A.G and c.2385T.C were expressed indepen-
dently or together in cis (R/NR: 115, 104, 113; NR/NR: 131, 128,
125), it seems plausible that the HEK293T cells were only able to
process and release the produced VWF at a similar rate, giving rise
to the greater increase in retained VWF observed.
Despite both SNV resulting in increased VWF levels, neither had a
direct effect on VWF protein structure/function or any effect on
mRNA splicing (supplemental Methods; supplemental Figure 4).
This is not unexpected because any major impact on protein
function or mRNA splicing would likely result in a more profound
(disease-causing) phenotype which would be observed in a
substantial number of individuals (given a general population
frequency of ;33% for both SNV). Instead, the increased levels
of VWF correspond to an increase in mRNA resulting, at least in
part, from both SNV prolonging the mRNA half-life. The reason for
this increased mRNA half-life is likely due to the influence of both
SNV on mRNA secondary structure as this is known to influence
RNA stability, which in turn impacts mRNA half-life.36 The fact that
replacement of an A or T nucleotide by either a C or G (which is the
case for both SNV) is reported to increase mRNA stability,42
supports this argument.
Plasma levels of VWF can be regulated by both biosynthetic and
clearance-related mechanisms.40 Support for the influence of
c.2365A.G and c.2385T.C genotype on clearance was ob-
served in a recent association study which demonstrated that while
the NR allele for c.2365A.G was linked to an increase in both
VWF:Ag and VWFpp levels, the effect size observed was smaller
for VWFpp, which the authors attributed to a clearance-dependent
mechanism.43 Data on VWFpp levels (although not significant, likely
due to data only being available for n 5 389 HCs) in this current
study confirm the effect size observation, whereas the VWFpp/
VWF:Ag ratios support the clearance-dependent mechanism
hypothesis as the NR allele was associated with a lower VWFpp/
VWF:Ag ratio.
Finally, VWF/FVIII DKO mice expressing the humanized reference
allele demonstrated decreased VWF:Ag levels compared with WT
mVWF, consistent with human plasma VWF:Ag results. mVWF
expressing both SNVs also had a shorter half-life than WT,
consistent with the VWFpp and VWFpp/VWF:Ag ratio observa-
tions in the HCs and as previously reported.43 Importantly,
accelerated clearance of mVWF expressing both SNVs impaired
stabilization of endogenous FVIII:C, which may account in part for
the association of these SNVs with plasma FVIII:C in normal
individuals. Although the influence of the SNVs was more
pronounced for humanized mVWF than observed in HCs, this
may relate to differences in the physicochemical influence of these
SNVs on hVWF vs mVWF, and recognition by their respective
clearance receptors. Alterations in the VWF amino acid sequence,
glycosylation pattern and 3D conformation may influence VWF
clearance by cells in the liver or spleen.40 Although the specific
mechanistic basis by which these SNV modify VWF half-life is not
defined, it is plausible that the changes alter the affinity of mVWF for
1 or more VWF clearance receptors.
There is increasing evidence that frequently observed SNVs can
affect protein function, expression, and clearance. Increased un-
derstanding of the genetic factors influencing VWF levels has
important implications given that variation in VWF levels is associated
with susceptibility to both bleeding and thrombosis. Nonfunctional or
reduced levels of VWF can result in von Willebrand disease
(VWD).44 Coinheritance of c.2365A.G and/or c.2385T.C with a
known pathogenic VWF mutation causing VWD could potentially
influence patient phenotype, for example, increasing VWF levels
resulting in a less severe phenotype, and may contribute to reduced
penetrance/variable expressivity observed in type 1 VWD.44
High VWF levels have been associated with increased risk of venous
thrombosis (VT), myocardial infarction and ischemic stroke.45-47
Inheritance of c.2365A.G has already been associated with an
increased risk of VT in female patients48 and as this SNV and
c.2385T.C result in increased VWF levels, they could both confer
an increased disease risk in other thrombotic disorders. Likewise,
African Americans have a higher risk of thrombosis compared with
other racial groups.49 Given that the reported minor allele
frequency for these SNVs is 57% in African Americans, compared
with;33% in Caucasians and 9% in East Asians,17 it is plausible
that these SNVs may contribute to this increased risk.
In conclusion, both c.2365A.G and c.2385T.C independently
cause an increase in VWF plasma levels. This is due to an influence on
VWF biosynthesis (similar to the c.7970G.A [p.R2657Q] gain-of-
function variant previously reported in mice)50 resulting from increased
mRNA production of variant VWF and to secreted variant VWF protein
having a greater half-life in the circulation. Inheritance of either or both
SNVs could have a significant impact on the risk/severity of hemostatic
and/or thrombotic disorders. In addition, these findings highlight that
common SNVs can have a direct influence on protein levels and care
should be taken before classifying common SNVs as “neutral” or
“benign.”
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